SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-045371
Filing Date
2024-11-14
Accepted
2024-11-14 08:30:36
Documents
14
Period of Report
2024-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 36993
2 ex99-1.htm EX-99.1 130028
  Complete submission text file 0001493152-24-045371.txt   356934

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE zvsa-20241114.xsd EX-101.SCH 3012
4 XBRL LABEL FILE zvsa-20241114_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE zvsa-20241114_pre.xml EX-101.PRE 24163
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3815
Mailing Address 217 W. MAIN STREET SOMERVILLE NJ 08876
Business Address 217 W. MAIN STREET SOMERVILLE NJ 08876 908-370-5102
ZyVersa Therapeutics, Inc. (Filer) CIK: 0001859007 (see all company filings)

IRS No.: 862685744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41184 | Film No.: 241457379
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)